Allianz Asset Management GmbH reduced its stake in shares of Bruker Co. (NASDAQ:BRKR) by 7.9% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 318,265 shares of the medical research company’s stock after selling 27,330 shares during the quarter. Allianz Asset Management GmbH owned approximately 0.20% of Bruker worth $9,468,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently modified their holdings of BRKR. Renaissance Technologies LLC lifted its stake in shares of Bruker by 106.6% during the 1st quarter. Renaissance Technologies LLC now owns 59,110 shares of the medical research company’s stock worth $1,379,000 after purchasing an additional 30,500 shares during the last quarter. Aperio Group LLC lifted its stake in shares of Bruker by 9.6% during the 2nd quarter. Aperio Group LLC now owns 19,362 shares of the medical research company’s stock worth $558,000 after purchasing an additional 1,699 shares during the last quarter. Sei Investments Co. lifted its stake in shares of Bruker by 33.3% during the 2nd quarter. Sei Investments Co. now owns 82,069 shares of the medical research company’s stock worth $2,367,000 after purchasing an additional 20,508 shares during the last quarter. Canada Pension Plan Investment Board lifted its stake in shares of Bruker by 97.4% during the 2nd quarter. Canada Pension Plan Investment Board now owns 139,000 shares of the medical research company’s stock worth $4,009,000 after purchasing an additional 68,600 shares during the last quarter. Finally, Schwab Charles Investment Management Inc. lifted its stake in shares of Bruker by 5.8% during the 2nd quarter. Schwab Charles Investment Management Inc. now owns 555,025 shares of the medical research company’s stock worth $16,007,000 after purchasing an additional 30,500 shares during the last quarter. Hedge funds and other institutional investors own 65.63% of the company’s stock.

BRKR has been the subject of a number of analyst reports. Citigroup upped their price objective on Bruker from $29.00 to $34.00 and gave the stock a “neutral” rating in a research note on Friday, November 3rd. Zacks Investment Research cut Bruker from a “buy” rating to a “hold” rating in a research note on Friday, November 10th. Goldman Sachs Group restated a “sell” rating and set a $24.00 price objective on shares of Bruker in a research note on Tuesday, September 26th. Morgan Stanley restated an “equal weight” rating and set a $35.00 price objective on shares of Bruker in a research note on Thursday. Finally, J P Morgan Chase & Co upgraded Bruker from an “underweight” rating to a “neutral” rating and set a $28.00 price objective for the company in a research note on Friday, November 3rd. Two investment analysts have rated the stock with a sell rating, eleven have given a hold rating and four have given a buy rating to the stock. The stock currently has a consensus rating of “Hold” and a consensus price target of $30.08.

Bruker Co. (NASDAQ BRKR) opened at $34.63 on Friday. Bruker Co. has a 1 year low of $21.03 and a 1 year high of $36.53. The stock has a market capitalization of $5,387.15, a PE ratio of 29.60, a P/E/G ratio of 2.93 and a beta of 1.12. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.60 and a current ratio of 2.60.

Bruker (NASDAQ:BRKR) last announced its earnings results on Thursday, November 2nd. The medical research company reported $0.29 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.27 by $0.02. Bruker had a return on equity of 25.83% and a net margin of 8.85%. The company had revenue of $435.60 million for the quarter, compared to analyst estimates of $415.45 million. During the same period in the prior year, the company posted $0.32 EPS. The firm’s quarterly revenue was up 10.6% compared to the same quarter last year. equities analysts predict that Bruker Co. will post 1.19 earnings per share for the current fiscal year.

The firm also recently announced a quarterly dividend, which will be paid on Friday, December 22nd. Investors of record on Monday, December 4th will be given a dividend of $0.04 per share. This represents a $0.16 annualized dividend and a yield of 0.46%. The ex-dividend date is Friday, December 1st. Bruker’s dividend payout ratio is currently 17.02%.

ILLEGAL ACTIVITY WARNING: This report was first reported by Watch List News and is the sole property of of Watch List News. If you are accessing this report on another site, it was stolen and reposted in violation of international copyright & trademark law. The original version of this report can be read at https://www.watchlistnews.com/allianz-asset-management-gmbh-lowers-holdings-in-bruker-co-brkr/1769120.html.

Bruker Company Profile

Bruker Corporation designs and manufactures scientific instruments, and analytical and diagnostic solutions. Its segments include the Bruker BioSpin Group; the Bruker Chemicals, Applied Markets, Life Science, In-Vitro Diagnostics, Detection (CALID) Group; the Bruker Nano Group, and the Bruker Energy & Supercon Technologies (BEST) Segment.

Want to see what other hedge funds are holding BRKR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bruker Co. (NASDAQ:BRKR).

Institutional Ownership by Quarter for Bruker (NASDAQ:BRKR)

Receive News & Ratings for Bruker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bruker and related companies with Analyst Ratings Network's FREE daily email newsletter.